Company news
Eloxx Pharmaceuticals, Inc. news in 2017
Eloxx Pharmaceuticals, Inc.'s news releases, calls and decks from 2017, newest first.
UPDATE -- Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer
December 27, 2017
Sevion Therapeutics Announces 1-for-20 Reverse Stock Split
December 19, 2017
Eloxx Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial
November 27, 2017
Eloxx Pharmaceuticals Announces Expansion of Intellectual Property Estate for ELX-02 with Newly Granted Patent in Europe
October 16, 2017
Eloxx Pharmaceuticals Appoints Gregory Weaver as Chief Financial Officer
September 26, 2017
Eloxx Pharmaceuticals Expands Management Team to Support Rapid Development of Lead Drug Candidate ELX-02 for the Treatment of Rare Genetic Diseases
September 8, 2017
Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 million
August 2, 2017
Eloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to Advance a Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis
June 26, 2017
Sevion Therapeutics Inc. and Eloxx Pharmaceuticals Ltd Announce the Entering into of an Acquisition Transaction
June 2, 2017